Shalom Jacobovitz
Director/Board Member at CLENE INC.
Net worth: 31 894 $ as of 30/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Reed Wilcox | M | 76 |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| Robert Dee Etherington | M | 57 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| David Matlin | M | 62 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Vallerie Mclaughlin | M | 60 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 3 years |
| Henrik Ørum | M | - |
CiVi Biopharma, Inc.
 CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE.
CiVi Biopharma Holdings, Inc.
 CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | 8 years |
| Mark Mortenson | M | 65 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 11 years |
| Alison Mosca | F | 51 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 5 years |
| Aaron Davis | M | 45 |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE.
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA. | 8 years |
| Chidozie Ugwumba | M | 41 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Jonathon Gay | M | 47 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 4 years |
| Morgan Brown | M | 55 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 2 years |
| Jerome T. Miraglia | M | 65 | - | |
| Arjun Desai | M | 42 | 1 years | |
| Christopher Fuglesang | M | 56 |
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA.
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | - |
| Carole Nüchterlein | F | 63 |
CiVi Biopharma Holdings, Inc.
CiVi Biopharma Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services CiVi Biopharma Holdings, Inc. operates as a clinical stage research and development biotechnology company. It create novel cardiovascular and metabolic therapies that have meaningful value to patients. The company is headquartered in Bryn Mawr, PA.
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | 7 years |
| Robert C. Gay | M | 72 |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | 6 years |
| Matthew Kiernan | M | 57 | 1 years | |
| Chad Young | M | - |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | - |
| David Lisonbee | M | - |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | - |
| Michael Hotchkin | M | 50 | - | |
| Mary Anne Moore McNeil | F | - | - | |
| Kevin Christal | M | - |
CiVi Biopharma, Inc.
CiVi Biopharma, Inc. Pharmaceuticals: MajorHealth Technology CiVi Biopharma, Inc. engages in the research and development of activities focusing on creating novel therapies against cardiovascular and metabolic diseases. The company was founded by Henrik Rum in 2016 and is headquartered in Wilmington, DE. | 6 years |
| Austin Rynders | M | - | - | |
| Benjamin Greenberg | M | - | 1 years | |
| Adam Dorfman | M | - | 11 years | |
| D. Pierce | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Eugenia Rutenberg | F | - |
Actelion Pharmaceuticals US, Inc.
 Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | 9 years |
| Paul Mirabelle | M | 66 |
University of Western Ontario
| 3 years |
| Roger Mortimer | M | - |
University of Western Ontario
| 6 years |
| Christopher DiFrancesco | M | 60 |
University of Western Ontario
| 7 years |
| Stephen Poloz | M | 68 |
University of Western Ontario
| 3 years |
| Geoffrey P. Cornish | M | - |
University of Western Ontario
| 7 years |
| Douglas Porter | M | - |
University of Western Ontario
| 6 years |
| John Stevens | M | 63 | 10 years | |
| Bruce Levitt | M | - |
University of Western Ontario
| 4 years |
| William Middleton | M | - |
University of Western Ontario
| 7 years |
| Paul Raymond Badeski | M | - |
University of Western Ontario
| 7 years |
| Robert G. Mulligan | M | - |
University of Western Ontario
| 7 years |
| David Martin | M | - |
University of Western Ontario
| 16 years |
| Fiona E. Costello | M | 54 | - | |
| Mario Charles Vachon | M | - |
University of Western Ontario
| 6 years |
| Steve Kearns | M | - |
University of Western Ontario
| 6 years |
| Jay G. Goldman | M | 61 |
University of Western Ontario
| 5 years |
| Christopher Harrs | M | 63 |
University of Western Ontario
| 7 years |
| Angus Blythe Rogers | M | - |
University of Western Ontario
| 4 years |
| Louis de Jong | M | - |
University of Western Ontario
| 4 years |
| James Swanson | M | - |
University of Western Ontario
| 4 years |
| Kevin Shea | M | - |
University of Western Ontario
| 4 years |
| Elisabeth DeMarco | F | 56 |
University of Western Ontario
| 4 years |
| Clive Owen Llewellyn | M | - |
University of Western Ontario
| 4 years |
| Peter Pisters | M | 63 |
University of Western Ontario
| 4 years |
| Paul Woods | M | - |
University of Western Ontario
| 4 years |
| Michael G. Hamilton | M | - |
University of Western Ontario
| 4 years |
| Joseph Anthony MacLean | M | 56 |
University of Western Ontario
| 4 years |
| Tang Tyrol | M | 61 |
University of Western Ontario
| 4 years |
| Norah Joyce | F | - |
University of Western Ontario
| 3 years |
| Gadi Mayman | M | - |
University of Western Ontario
| 2 years |
| Timothy J. Counsell | M | 66 |
University of Western Ontario
| 3 years |
| Abbie Gagne | F | - |
University of Western Ontario
| 4 years |
| Donald James Rae | M | 63 |
University of Western Ontario
| 2 years |
| Paul Rosen | M | 60 |
University of Western Ontario
| 4 years |
| Youtaz Irani | F | - |
University of Western Ontario
| 4 years |
| Scott McLean | M | 62 |
University of Western Ontario
| 4 years |
| Peter Manojlovic | M | - |
University of Western Ontario
| 4 years |
| Robert McKague | M | 60 |
Actelion Pharmaceuticals US, Inc.
Actelion Pharmaceuticals US, Inc. Pharmaceuticals: MajorHealth Technology Part of Johnson & Johnson, Actelion Pharmaceuticals US, Inc. is a private company that manufactures, distributes and markets drugs. The company is based in Titusville, NJ. The CEO of the company is Samuele Butera. | 1 years |
| Martin Lochran | M | - |
University of Western Ontario
| 4 years |
| Oliver Kuhn | M | - |
University of Western Ontario
| 4 years |
| D. Andrew Cook | M | 61 |
University of Western Ontario
| 4 years |
| Andrew Morris | M | - |
University of Western Ontario
| 4 years |
| G. Stephen Dembroski | M | - |
University of Western Ontario
| 4 years |
| William Beattie | M | 64 |
University of Western Ontario
| 3 years |
| Rob Lyman Jackson | M | - |
University of Western Ontario
| 3 years |
| Robert J. Fuller | M | - |
University of Western Ontario
| 4 years |
| Gus Papageorgiou | M | - |
University of Western Ontario
| 5 years |
| Glen R. Estill | M | - |
University of Western Ontario
| 2 years |
| Paul Baay | M | 61 |
University of Western Ontario
| 4 years |
| Kenneth Lapierre | M | 66 |
University of Western Ontario
| 4 years |
| Donald Hoy | M | 68 |
University of Western Ontario
| 4 years |
| Roger O. MacLeod | M | - |
University of Western Ontario
| 3 years |
| Sing Yam Fu | M | 62 |
University of Western Ontario
| 4 years |
| James R. Swayze | M | 60 |
University of Western Ontario
| 4 years |
| Thomas Cannon | M | - |
University of Western Ontario
| 4 years |
| Mark R. McQueen | M | - |
University of Western Ontario
| 4 years |
| Perry Dellelce | M | - |
University of Western Ontario
| 4 years |
| Matthew C. Wunder | M | - |
University of Western Ontario
| 4 years |
| Richard Young | M | 60 |
University of Western Ontario
| 4 years |
| Roger Brent Fulton | M | 62 |
University of Western Ontario
| 3 years |
| Alfred A. Jay | M | - |
University of Western Ontario
| 4 years |
| Kimberley Okell | F | - |
University of Western Ontario
| 4 years |
| Roy Thomas Graydon | M | 62 |
University of Western Ontario
| 2 years |
| Pierre J. Schuurmans | M | - |
University of Western Ontario
| 4 years |
| Henry C. Eaton | M | - |
University of Western Ontario
| 2 years |
| Rick Musial | M | - |
University of Western Ontario
| 4 years |
| Colin Foster | M | 61 |
University of Western Ontario
| 2 years |
| Kathleen Dorey | F | - |
University of Western Ontario
| 4 years |
| Daniel Burns | M | 63 |
University of Western Ontario
| 4 years |
| Michael Berry | M | 58 |
University of Western Ontario
| 4 years |
| Zoran Vukasinovic | M | - |
University of Western Ontario
| 4 years |
| David W. Clayton | M | - |
University of Western Ontario
| 4 years |
| Shane O'Leary | M | 67 |
University of Western Ontario
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 70 | 70.00% |
| United States | 30 | 30.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Shalom Jacobovitz
- Personal Network
